Skip to main content
SpringerLink
Log in

ADR reporting rate greater for valsartan than other ARBs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Salim H, et al. Angiotensin II Receptor Blockers (ARBs) and Manufacturing Contamination: A Retrospective National Register Study into suspected associated adverse drug reactions British Journal of Clinical Pharmacology : 23 May 2022. Available from: URL: http://doi.org/10.1111/bcp.15411

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ADR reporting rate greater for valsartan than other ARBs. Reactions Weekly 1908, 5 (2022). https://doi.org/10.1007/s40278-022-15733-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-15733-7

Search

Navigation